Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Q702 |
Synonyms | |
Therapy Description |
Q702 selectively inhibits Axl, Mertk, and Csf1r, which may relieve immunosuppression in the tumor microenvironment and increase infiltration of immune cells into tumors, potentially leading to tumor regression (AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4974) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Q702 | Q 702|Q-702 | AXL Inhibitor 30 CSF1R Inhibitor 28 MERTK Inhibitor 13 | Q702 selectively inhibits Axl, Mertk, and Csf1r, which may relieve immunosuppression in the tumor microenvironment and increase infiltration of immune cells into tumors, potentially leading to tumor regression (AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4974) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04648254 | Phase I | Q702 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor | Recruiting | USA | 0 |